ABBV
Two shots on goal
AbbVie came out swinging with clinical updates on Wednesday, and the message was basically: the pipeline isn’t just alive, it’s doing cardio.
First up was zumilokibart, AbbVie’s Phase 2 eczema candidate. In the APEX Part B study, the drug beat placebo across every evaluated dose in adults with moderate to severe atopic dermatitis, with the higher and mid doses also clearing key secondary endpoints. Translation: the skin got calmer, the itch dial turned down, and the data looked good enough to make investors sit up a little straighter.
The itch factor matters
For an immunology company, this is the kind of result that can move the story from “nice research project” to “okay, now we’re talking real commercial potential.” AbbVie said the mid-dose group saw rapid improvements by Week 1 and itch relief by Week 2, which is the kind of fast readout that makes a trial feel less like a science fair and more like a viable medicine.
Then came the weight-loss plot twist
AbbVie also shared Phase 1 data for ABBV-295, its amylin analog, at the European Association for the Study of Diabetes 2026 Annual Meeting. Participants saw dose-dependent weight loss of roughly 7.8% to 9.8% over 12 to 13 weeks, while the drug’s half-life suggested the dosing schedule could be stretched out like a weekend binge-watch, not a daily chore.
That matters because the obesity market is already crowded, loud, and extremely expensive. A non-GLP-1 option with workable tolerability and decent durability gives AbbVie another angle of attack.
Big picture
AbbVie’s share price barely blinked in the moment, but pipeline data like this can slowly rewrite the bull case. If these programs keep progressing, the company isn’t just a dividend-and-defensives name — it’s also trying to be a growth story in immunology and metabolic disease. And that’s a much more interesting movie.